Open Orphan Plc stock analysis
Open Orphan Plc (CRO) Stock Price & Analysis
CRO Stock Chart & Stats
- Day’s Range
- EUR 0.05 - EUR 0.05
- 52-Week Range
- EUR 0.04 - EUR 0.13
- Previous Close
- EUR 0.06
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 42.91M
- Enterprise Value
- EUR 47.72M
- Total Cash (Recent Filing)
- EUR 12.98M
- Total Debt (Recent Filing)
- EUR 13.92M
- Price to Earnings (P/E)
- ―
- Beta
- 0.31
- Next Earnings
- Apr 14, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.63%
Bulls Say, Bears Say
Bulls Say
Record Order Book
The record order book provides stronger revenue visibility beyond the current reporting period, with management citing coverage into 2027 and 2028. This supports capacity planning, improves confidence in future utilization, and can help the company convert its expanded sales pipeline into sustained growth.
Differentiated Trial Infrastructure
Rapid study delivery and specialized infrastructure can make hVIVO valuable to biopharma customers seeking faster clinical evidence. Its dedicated facilities, volunteer database and infectious-disease expertise are established capabilities that may support repeat demand and defend its position in human challenge trials.
Accretive CRS Berlin Acquisition
The acquisition broadens hVIVO's service offering while adding an already profitable and cash-generative operation. Its contracted revenue base and expected EBITDA contribution can support earnings diversification, while the added clinical capacity and therapeutic reach create opportunities for longer-term cross-selling.
Bears Say
Sharp Profitability Deterioration
The latest annual results show that hVIVO's earnings profile remains vulnerable to changes in project timing and revenue mix. Negative gross profit and a sizable net loss reduce internal funding capacity, weaken resilience, and make a durable return to profitability dependent on operational recovery.
High Cash Burn And Lower Cushion
Deeply negative cash generation reduces the funds available for investment and leaves less room to absorb further delays in clinical work. The expected year-end cash reduction increases reliance on existing balance-sheet resources or external funding if the anticipated recovery does not materialize.
Contract Deferrals And Margin Pressure
Deferred projects weaken near-term revenue visibility even though management says they were not canceled. The lower-margin second-half mix further limits operating leverage, while repeated timing shifts could prolong losses and make the path to consistent positive EBITDA less predictable.
CRO FAQ
What was Open Orphan Plc’s price range in the past 12 months?
What is Open Orphan Plc’s market cap?
When is Open Orphan Plc’s upcoming earnings report date?
How were Open Orphan Plc’s earnings last quarter?
Is Open Orphan Plc overvalued?
Does Open Orphan Plc pay dividends?
What is Open Orphan Plc’s EPS estimate?
How many shares outstanding does Open Orphan Plc have?
What happened to Open Orphan Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Open Orphan Plc?
What is the TipRanks Smart Score and how is it calculated?
Open Orphan Plc Stock Smart Score
Company Description
Open Orphan Plc
hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Yamin Mohammed Khan
- Employees
- 376
- Website
- www.hvivo.com
- Address
- 40 Bank Street, London, GL, E14 5NR, GB
Open Orphan Plc (CRO) Earnings & Revenues
CRO Earnings Call
Earnings Call SentimentPositive
The call was positive overall despite weak first-half financial results, a GBP 47 million full-year revenue outlook below consensus, contract delays and an expected full-year EBITDA loss. Management emphasized record order-book levels, a recovering human challenge trial pipeline, 110% laboratory revenue growth, diversification into new therapeutic areas and an immediately accretive CRS Berlin acquisition. The deferred contracts were explicitly described as delayed rather than canceled, and management expressed confidence in significant growth and positive EBITDA in 2027.
View all DE:CRO earnings summariesCRO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
